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Abstract 
    Background: The world is facing a pandemic of COVID-19, a respiratory disease caused by a novel coronavirus which is now called 
SARS-CoV-2. Current treatment recommendations for the infection are mainly repurposed drugs based on experience with other 
clinically similar conditions and are not backed by direct evidence. Chloroquine (CQ) and its derivative Hydroxychloroquine (HCQ) are 
among the candidates. We aimed to synthesize current evidence systematically for in vitro, animal, and human studies on the efficacy 
and safety of chloroquine in patients with COVID-19. 
   Methods: The Cochrane Library, Google Scholar, PubMed (via Medline), Embase, Scopus, and Web of Science, MedRxiv, clinical 
trial registries including clinicaltrials.gov, ChiCTR (Chinese Clinical Trial Registry), IRCT (Iranian Registry of Clinical Trials), and the 
EU Clinical Trials Register. We used the Cochrane tool for risk of bias assessment in randomized studies, the ROBINS tool for non-
randomized studies, and the GRADE methodology to summarize the evidence and certainty in effect estimates. 
   Results: The initial database searching retrieved 24,752 studies. Of these, 15,435 abstracts were screened and 115 were selected for 
full-text review. Finally, 20 human studies, 3 animal studies, and 4 in vitro studies were included in this systematic review. The risk of 
bias within studies was unclear to high and the overall certainty in evidence-based on GRADES- was very low. HCQ may be effective 
in clinical improvement in a subset of patients with COVID-19. However, the frequency of adverse events was higher in patients taking 
HCQ compared to standard of care alone. In contrast, animal studies, did not report any adverse effects. Furthermore, clear benefit of 
the drug in the survival of the animals has been reported. Most in vitro studies indicated a high selectivity index for the drug and one 
study that used a human coronavirus reported blockage of virus replication. 
   Conclusion: Current evidence background is limited to six poorly conducted clinical studies with inconsistent findings which fail to 
show significant efficacy for HCQ. Safety data is also limited but the drug may increase adverse outcomes. Routine use of the drug is 
not recommended based on limited efficacy and concerns about the drug safety especially in high-risk populations. 
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↑What is “already known” in this topic: 
The world is facing a pandemic of COVID-19, so it is essential 
to survey in vitro, animal, and clinical evidence background for 
the effectiveness and safety of Hydroxychloroquine for treating 
patients with COVID-19 in around the world. 
 
→What this article adds: 
There is insufficient evidence to draw conclusions on the efficacy 
and safety of chloroquine and Hydroxychloroquine based on 









































   
   
























From the black plague in the 14th century Europe to the 
cholera pandemics of the 19th century and the 1918 Spanish 
flu, epidemics have always been a subject of concern and a 
cause of mass mortality as well as considerable economic, 
social, and psycho logic harm to populations throughout 
history. The most recent one, to date, has been the COVID-
19 pandemic, caused by SARS-CoV-2, a member of the 
family Coronaviridae, that is mainly characterized by se-
vere acute respiratory syndrome. This virus appeared in 
China in December 2019 and rapidly spread worldwide, 
creating a public health emergency around the world in 6 
months. 
Since SARS-CoV2 is a novel pathogen, no standardized 
treatment is currently available. One proposed agent is 
chloroquine (CQ), classically known as an antimalarial and 
immunomodulatory agent. Preclinical evidence suggests 
that clinical research on CQ in COVID-19 patients is justi-
fied (1). In a previous SARS-CoV epidemic, it was pro-
posed that CQ could be considered as a treatment (2, 3). 
During the first months of the COVID epidemic, a letter-
to-the-editor claimed that CQ has shown efficacy and 
safety in an ongoing multicenter study in China for pneu-
monia caused by SARS-CoV-2, and it was recommended 
to be included in treatment regimens for COVID-19 pneu-
monia (4). Therefore, CQ and Hydroxychloroquine (HCQ) 
have been considered as potential treatments for COVID-
19. 
Whether systematic reviews of preclinical studies can ac-
curately predict clinical outcomes is controversial. How-
ever, preclinical research can provide useful information 
about the biological plausibility of human drug trials (5). 
Its special settings that enable direct study of the mecha-
nisms of disease as well as drug pharmacodynamics and 
pharmacokinetics can aid clinical decision-making (6).  
In this systematic review, we aimed to comprehensively 
synthesize in vitro, animal, and clinical evidence back-
ground for the effectiveness and safety of CQ, including its 
sulfate and phosphate salts, and Hydroxychloroquine for 
treating patients with COVID-19.  
 
Methods 
Protocol and Registration 
This systematic review was conducted under emergency 
conditions of the global coronavirus pandemic. The proto-
col was developed by a team of clinical epidemiologists 
(H.R.B. and Y.M.), physicians (H.R.B., MAK, and F.B.), 
and a librarian (R.V.A.). 
 
Eligibility Criteria 
Human controlled studies (including interventional and 
observational studies), animal studies, and in vitro studies 
evaluating the effect of CQ, Hydroxychloroquine, or other 
quinine derivatives on coronavirus infections, including 
SARS, MERS, and COVID-19, up to June 30, 2020 were 
included. No limitation was used based on language, pub-




The Cochrane Library, Google Scholar, PubMed (via 
Medline), Embase, Scopus, and Web of Science, MedRxiv; 
and clinical trial registries, including clinicaltrials.gov, 
ChiCTR (Chinese Clinical Trial Registry), IRCT (Iranian 




The search strategy was developed based on study ques-
tions and relevant key words by a medical librarian 
(R.V.A.) and a physician (F.B.) with systematic review ex-
perience for all information sources. An update search was 
done on July, 30, 2020 for further human studies.  
 
Study Selection 
All retrieved records were comprehensively screened 
based on title by 2 authors independently (F.B. and 
M.A.K.). Relevant studies were imported into a citation 
manager (Endnote X7) for screening the abstract after re-
moval of duplicated sources. The abstracts matching the el-
igibility criteria were selected and categorized into groups 
based on study type and participants by one reviewer 
(M.A.K. or F.B.) and the full-texts of the studies were re-
trieved. We contacted the authors when we could not access 
the full-texts. The full-texts of the in vitro studies as well as 
the animal models were reviewed by a virologist (B.S.). 
The full-texts of clinical studies were evaluated for eligibil-
ity by 2 physicians (F.B. and MAK). The references of in-
cluded articles were hand-searched for further relevant 
studies. 
 
Data Collection Process 
To ensure uniform and comprehensive data extraction 
among different data extractors, the reviewers developed 
Microsoft Access forms and tables, including information 
recommended in the Cochrane Handbook of Systematic 
Reviews of Interventions (7). These items included the 
name of the first author, publication year, region, descrip-
tions of study design, participants, interventions, compari-
sons, outcomes and results, as the sources of funding and 
key conclusions by the original study authors. Data were 
extracted by the same review authors who screened the ar-
ticle full-texts.  
 
Risk of Bias in Individual Studies 
Risk of bias within the clinical studies was assessed using 
the Cochrane risk of bias tool, which evaluates studies in 5 
domains and rates the study for each domain of bias as hav-
ing low, unclear, or high risk of bias (8). The ROBINS tool 
was used to assess risk of bias within nonrandomized stud-
ies. The SYRCLE’s tool was used to assess the risk of bias 
in animal studies (9). OHAT risk-of-bias tool was em-
ployed for in vitro studies (10, 11). The risk of bias for each 
study was assessed by 2 reviewers independently (F.B., 
B.S., Y.M.) and in case an agreement could not be reached 
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Summary Measures and Synthesis of Results 
Relative risk and relative risk reduction were used to 
summarize data for dichotomous outcomes, and mean dif-
ference was used for continuous variables. Because of the 
significant variation in study methodology and outcome 
measurements, a meta-analysis was not possible for most 
of the outcomes. Qualitative synthesis was done using the 
GRADE approach per study outcome. We followed the 
SWIM guidelines for reporting synthesis without meta-
analysis (12).Viral clearance was summarized as the odds 
ratio of the proportion of patients who tested negative on 




A total of 24,752 studies were retrieved by searching the 
mentioned databases, that were screened by title. Of these, 
15 435 abstracts were screened and 115 were selected for 
full-text review. The eligible studies were categorized at 
this stage based on their subject (in vitro, animal, and hu-
man studies) and were assigned to expert authors for full-
text review and final inclusion. Seven human studies were 
excluded based on full-text, as they were reviews or per-
spective articles. 
The update search retrieved 1628 studies that were 
screened by title by 1 author. A total of 248 abstracts were 
screened and 82 full-text articles were screened by 2 au-
thors independently. Finally, we included 18 non-random-
ized studies and 6 randomized human studies.  
The PRISMA flow diagram is presented in Figure 1. 
 
Study Characteristics 
Human Studies: We included 6 RCTs and 14 nonrandom-
ized controlled human studies, all of which were conducted 
among hospitalized patients. None of the studies were pla-
cebo-controlled. Also, pregnant and breastfeeding women 
as well as patients with underlying conditions were ex-
cluded. Most studies compared the recommended dose of 
HCQ daily (ranging from 400mgs/day to 800mgs/day) with 
drug regimens without HCQ/CQ. Also, 3 studies used a 
high dose of HCQ, 6 had AZI, and 2 had Lopinavir/ri-
tonavir as part of their control regimen. The follow-up du-
ration varied among the studies and ranged from 7 to 30 
days (Tables 1 and 2). 
 








































   
   















    













Table 1. The Risk of Bias within Randomized Controlled Trials 
ID First Author Random Sequence 
Generation 
Allocation Concealment Blinding of Participants 
and Personnel 




Selective Reporting Overall 
1 Chen, Zh1 L U U U L H L 
2 Chen, J2 U H H H U U H 
3 Tang, W3 L L H H U L H 
4 Borba, MGS4 L L U L L U L 
5 Cavalcanti, AB5 L U H H L L L 
6 Huang, M6 U L H H H L H 
 
Guide to the table:  Unclear RoB  Low RoB   High RoB 
 
1. Allocation concealment and blinding procedures were neither explained in the article nor in the protocol. The outcomes reported were completely different from the ones initially planned in the protocol. In the 
protocol, the researchers planned to evaluate viral clearance and immunologic response. However, they merely reported clinical outcomes in the article. 
2. Unclear description of randomization is given. Antiviral regimens were not the same between groups. 
3. Open-label randomized trial. With control group receiving standard care. Reporting of outcomes was complete and dropout frequency was 6 out of 75. Use of intervention varied among participants especially 
regarding the timing in relation to symptom onset. 
4. Randomized controlled trial. The pharmacist distributing the drugs was not blinded, which might have been the source of uncertainty in blinding of participants and personnel.  
5. Open-label randomized study with 6-item randomization blocks. Both the patients and the personnel were aware of the randomization group. Selective reporting was unlikely because the protocol was available, 
and all the predetermined outcomes have been reported. Appropriate use of intention-to-treat analysis makes it unlikely for incomplete reporting to affect study results. 
6. Open-label randomized study with 4-item randomization blocks (according to the protocol but not mentioned in the published report). There was a baseline difference between the groups in "days from onset to 
treatment." Concealment of randomization was done using sealed envelopes. The study protocol was available and the risk of selective reporting was low. However, the published results are preliminary and 









































   
   
































Table 2. The Risk of Bias within Non-Randomized Controlled Human Studies 
No First Author Bias due to Confound-
ing 
Selection Bias Classification Bias Deviation from Exposure Missing Data Measurement of Out-
comes 
Selective Reporting Overal 
1 Matthieu Mahévas L L L M L S NI M 
2 Gautret, Philippe M NI L L S M NI S 
3 Singh, Sh M M L S M NI NI S 
4 Sbidian M M L S S M NI S 
5 Rosenberg M L L S M S NI M 
6 Mehra, MR M L L M NI S NI M 
7 Mallat, J S S L S NI NI NI C 
8 Magagnoli L S M S L M L S 
9 Lagier, JC S S L NI S M NI C 
10 Geleris,J M M L S M L NI M 
11 Yu, B M M M S L L NI S 
12 Arshad, S M L L M L M NI M 
13 IP, A M M L M L M L M 
14 Mazzanti, L L L M L M L M 
 
Guide to the table:  L: Low RoB;  NI: No Information;  M: Moderate RoB;   S:Serious RoB;   C: Critical RoB 
 
1. Observational study with well-matched between-group baseline characteristics, and the same dosage of chloroquine for all patients. Inconsistency in measurement and recording of the outcomes is suspected. 
2. Children who usually have milder course of disease were not included to the treatment group, while they were included in the comparison group. No placebo was used in comparison group. Participants and personnel were not blinded. There was a 
high dropout rate (6/26) in the treatment group with reasons potentially relevant to the side effects of hydroxychloroquine, including admission to ICU and treatment cessation. An intention-to-treat analysis should have been used. 
3. Retrospective cohort analysis of hospital data. Patient selection based on international criteria. Confounding variables addressed by propensity scores in analysis. No information was given on how the exposure use was confirmed. No information was 
given on how outcomes were assessed. The study protocol was not available to assess the selective reporting. No information was given on missing data. 
4. Retrospective study of hospital data on PCR confirmed COVID19 patients. Augmented inverse probability of treatment weighted (AIPTW) estimates of the average treatment effect (ATE) were used to account for confounding. Data were extracted 
using artificial intelligence from data systems and manually from medical text reports. Exposures measured according to hospital-registered prescriptions only.  
5. Retrospective multicenter cohort. Random sample of patients admitted to 25 hospitals. The exposure dosage and regimens differed across the study sample. A low proportion of patients used HCQ alone. There was inadequate description of how 
outcome measurement and data extraction were done and there is a high risk of bias due to the variability in exposures and outcome measurements across hospitals. 
6. Multinational registry analysis (retrospective observational) on patients with PCR-confirmed COVID-19. Confounding was adjusted for in statistical analysis. No protocol was available; therefore, risk of bias due to selective reporting cannot be 
estimated. Outcome assessment is suspected to differ significantly across the study centers and due to the observational nature of the study.  
7. Retrospective observational study on patient data from 1 hospital. The study methodology was poorly reported. All patients had PCR-confirmed COVID-19. There was significant difference in the frequency of comorbidities between HCQ and control 
groups, and consequently, a serious risk of bias due to confounding. No information was given on missing data. No study protocol was available to confidently assess selective reporting. 
8. Retrospective observational study in 1 veterans' hospital. All patients had PCR-confirmed COVID19. Propensity score analysis was used to address confounding. Exposure was defined based on the information from hospital registry of drug dispens-
ing for each patient. No study protocol was available to assess selective reporting. Outcome assessment may cause moderate risk of bias due to the observational nature of the study. 
9. Retrospective cohort study. All patients had PCR and culture-confirmed COVID-19. Cardiovascular disease was more common among the control group. The treatment was initiated at an earlier stage of the infection in this study. It is not clear how 
exposure to the treatments was assessed. No study protocol was available to assess the risk of selective reporting.  
10. Retrospective observational study at a quaternary, acute care hospital. Patients had PCR confirmed COVID-19. Confounding was adjusted using propensity score matching/analysis. The exposure was evaluated by patient exposure to the drug before 
or during the admission and thus may vary across participants. No study protocol was available and risk of selective reporting could not be assessed.   
11. Retrospective observational study on critically-ill (selection bias) inpatients with CT and PCR-confirmed COVID19. There was no significant baseline difference in confounding variables between groups. Patient classification (based on dug exposure) 
may have been subject to error because mere prescription may not show drug use by the patient. No information is given on how the outcome measurements were standardized. 
12. A multicenter retrospective observational study on inpatients with PCR-confirmed COVID-19. Treatment regimens were uniform across hospitals. There was moderate risk of bias due to confounding because of the nonrandomized nature of the study 
and that HCQ was used among patients with more severe disease. This may underestimate the effects of chloroquine. This confounding was partially adjusted for statistically.  
13. Retrospective multicenter cohort based on HER data. The study design made it susceptible to bias due to confounding and misclassification. Drug administration was well documented. There was moderate risk of bias due to missing outcome data.   
14. Initial results of a prospective observational study with an available protocol. Patients had PCR-confirmed COVID-19. Confounding variables have been well adjusted for. Although the study was observational, enough documentation was performed 








































   
   















    
Chloroquine and Hydroxychloroquine for COVID-19 
 
Animal Studies: One of the animal studies used SARS-
CoV-1 in BALB/c female mice and tested the efficiency of 
Amodiaquine and CQ, with a dose response design detect-
ing the virus replication in lung homogenates. The other 2 
animal studies used HCoV-OC43 virus as the model. One 
of these 2 studies aimed at identifying the effect of CQ-sul-
phate in adult C57BL/6 mice followed by studying the pro-
tective effect of the drug transferred to litters by placenta or 
milk of the drug treated mothers. The other study optimized 
the detection of a luciferase labelled virus in adult BALB/c 
mice but used the drug CQ as a control to block the virus 
replication and control the background luciferase detection 
in treated mice. The study characteristics of the 3 animal 
studies are summarized in Table 3 in Appendix. 
Interestingly, 2 of the animal studies included in vitro ex-
aminations as part of their design, which were added to the 
in vitro studies. 
 
Risk of Bias within Studies 
Among the 6 randomized human studies included to the 
systematic review, the risk of bias due to random sequence 
generation was unclear among 2 studies. Allocation con-
cealment introduced a high risk of bias in 1 study and was 
unclear in 2 other studies. Only 1 study was blinded. Two 
studies were at high risk of bias due to incomplete outcome 
data, and 1 study was at high risk of bias due to selective 
reporting. The details are presented in Table 4. 
Among the 14 nonrandomized human studies, 7 were at 
moderate overall risk of bias, 5 were at serious risk, and 2 
had a critical risk of bias. The details are presented in Table 
5. 
Risk of bias was also assessed in animal studies, and they 
were found to be generally reliable (Table 6).  
 
Synthesis of Results 
Human Studies: Because of the heterogeneity in the type 
of included studies, different methods of outcomes assess-
ment, and the statistical methods for summarizing the re-
sults, we could not combine the results in a meta-analysis. 
Therefore, we synthesized the results qualitatively.  
Clinical Response: One study showed a reduced mean of 
days of having fever for patients in the HCQ group com-
pared to the control (2.2 vs 32) and another study showed 
fewer number of days with fever for the HCQ group com-
pared to the control group. Taking HCQ was also associ-
ated with shortened duration of cough in 1 study (an aver-
age of 2 vs 3.1 days). In 1 study, administering HCQ was 
related to a higher rate of clinical improvement within a 
course of 28 days, whereas in 2 other studies, HCQ treat-
ment was associated with a higher rate of progression to 
severe illness. 
Adverse Events: The most notable adverse events were 
GI events, death due to unclear cause, and cardiac adverse 
events, all of which were more prevalent among the HCQ 
groups compared to controls (SOC). One study that consid-
ered the incidence of “any” adverse event showed a higher 
incidence among the HCQ group compared to that of the 
control group. The incidence of other symptoms, such as 
headache, rashes, nausea, and weakness, were low in both 
groups, without a significant difference between the HCQ 
and the control groups. 




















Dale L Barnard1 
2006 
5 5 1 3 1 1 4 3 
Els Keyaerts2 
2009 
2 3 2 3 1 2 3 3 
Junwei Niu3 
2020 
2 2 2 1 1 1 4 5 
 
Scoring system: Definitely High =1 Probably High = 2 Probably Low = 3 Definitely Low = 4 Unclear = 5 
 
1. The reporting of the outcome and the statistical methods were appropriate. 
2. The presentation on the design of the study has some mistakes and the outcome based on the published design is suboptimal. 
3. The number of animals used in the experiment was not clear. 
 
Table 4. Virological Response 
Outcome Study Outcome description Study design HCQ Control Effect Estimates p 
Viral clearance 
after 14 days 
Mingxing 
Huang 
































8/16 14/16 0.142 (0.024–0.844) 0.03 
Mingxing 
Huang 




9/10 9/10 1.00 (0.053–18.57) 0.99 
Tang, W Proportion of PCR negative on 
day 6 
Randomized trial 34/75 41/75 0.687 (0.36–1.30) 0.25 
Lagier Proportion of PCR negative 
after 10 days 
Retrospective co-
hort 
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Tables 4 to 6 present the synthesis of the effect estimates 
per outcome and Table 7 is the summary of findings in 
GRADE format. 
Animal Studies: Two animal studies showed the effec-
tiveness of CQ in mice models using a wild type HCoV-
OC43 and another recombinant rOC43-ns2DelRluc from 
 
Table 5. Clinical improvement 
Outcome Study  Hydroxychloroquine Control Effect Estimate  
(Odds Ratio) Or 
Mean Difference 
(SD) with Standard-
ized Mean  
Difference 95 % CI 
p 
Fever Chen, Zh Mean days (SD) 2.2 (0.4) 3.2 (1.3) 1.00 (0.51-1.48) 0.0001 
Chen, J Median (range) 1 (0-2) 1 (0-3) 0.00 (-0.50-0.50) 0.98 
Cough 
 




Tang, The improvement rate of clini-
cal symptoms within 28-day 
47/70 48/80 1.36 (0.69-2.66) 0.36 
Discharge home or 
to a rehab center 
Sbidian Number of patients 351/623 1507/3792 1.95 (1.64-2.32) 0.001 
Magagnoli Number of patients 70/97 140/158 2.92 (1.77-4.81) 0.001 
Mingxing 
Huang 
Proportion of hospital discharge 
on day 14 
10/10 6/12 - - 
Mahevas Proportion of patients dis-
charged by day 21 
67/84 71/89 1(0.9-1.2)  
Clinical progres-
sion to severe ill-
ness 
Chen, Zh Rate of Progression to severe ill-
ness 
4/31 0/31 - - 
Lagier Combined death/ICU admis-
sion/long hospitalization 
8/101 13/162 0.98 (0.39-2.46) 0.97 
Mean length of 
hospital stay 
Cavalcanti Duration of hospital stay 
 





Proportion of CT-scan improve-
ment (day 10) 
7/10 5/12 3.26 (0.55-19.25) 0.19 
Proportion of CT-scan improve-
ment (day 14) 
10/10 9/12 - - 
 
Table 6. Adverse events 
Outcome  
category 
Outcome Study Hydroxychloroquine Control Effect Estimate (Odds Ra-
tio) Or Mean Difference 
(SD) with Standardized 
Mean Difference 95 % CI 
p 
Fatal outcomes Death (any cause) Sbidian 111/623 865/3792 0.781 (0.630–0.968) 0.02 
Gautret, P 1/26 0/16 -  
Rosenberg 54/271 28/221 1.715 (1.044–2.816) 0.03 
Singh 104/910 109/910 0.948 (0.71–1.26) 0.14 
Lagier 2/101 4/162 0.798 (0.14–4.43) 0.79 
Magagnoli 27/97 18/158 3.00 (1.54–5.81) 0.001 
Yu, B 9/48 238/502 0.25 (0.12–0.53) 0.001 
Cavalcanti, AB 7/159 6/173 1.28 (0.42–3.89) 0.6 




Mahevas 9/84 8/89 1.2 (0.5-3)  
Geleris 262/811 84/565 2.73 (2.07–3.59) 0.000 
Mahévas, M 3/84 4/97 0.86 (0.18–3.96) 0.84 
















Arrhythmia Rosenberg 44/271 23/221 1.668 (0.972–2.860) 0.06 
QT prolongation Rosenberg 39/271 13/221 2.689 (1.397–5.17) 0.003 
Nicholas J Mercuro 3/37 7/53 0.579 (0.14–2.40) 0.45 

















ICU transfer Singh 46/910 57/910 0.796 (0.53-1.18) 0.26 
Cavalcanti, AB 12/159 12/173 1.09 (0.47-2.51) 0.83 
Rosenberg 55/271 27/221 2.19 (1.16–4.11) 0.01 
Sbidian 206/623 739/3792 2.04 (1.69-2.45)  
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8 
which the ns-2 gene was replaced with a reporter gene. In 
both models, intracerebral inoculation of the virus was 
treated with CQ and improved the survival of the infected 
mice compared with the animals in the control group. The 
models were not similar: one study examined survival in 
suckling mice but the other assessed survival of adult mice. 
Also, the viruses were not identical in the 2 models. CQ in 
another mice model did not block infection by SARS-CoV. 
Table 6. Ctd 
Outcome  
category 
Outcome Study Hydroxychloroquine Control Effect Estimate (Odds 
Ratio) Or Mean Differ-
ence (SD) with Standard-





















Nausea Gautret, P 1/26 0/16 -  
Mingxing Huang 4/10 0/12 -  
















Mingxing Huang 5/10 0/12 -  
Rash Chen, Zh 1/31 0/31 -  
Hypoglycemia Rosenberg 9/271 6/221 1.230 (0.44–3.51) 0.38 
Paresthesia Tang 9/80 2/80 4.943 (1.03–23.65) 0.04 
Paresthesia 
Weakness 
Chen, J 1/13 0/14 -  
 
Table 7. GRADE summary of findings table 
Outcomes № of participants  
(studies)  





assessed with: negative 
throat swabs on day 6-7 
post-enrollment  
232 
(9 RCTs)   
VERY LOW a,b,c,d 
The evidence is very uncertain about the effect of hydroxychlo-
roquine on the rate of viral clearance after one week of treat-
ment. There are two RCTs, two non-randomized trials, and two 
retrospective cohort studies with significantly inconsistent re-
sults.  
Symptom Improvement  286 
(4 RCTs)   
VERY LOW a,b,e,f,g 
The evidence is very uncertain about the effect of hydroxychlo-
roquine on symptom Improvement. The study results are incon-
sistent and inconclusive. 
Radiological Progression  89 
(2 RCTs)   
VERY LOW d,l 
Hydroxychloroquine may have little positive to no effect on ra-
diological progression but the evidence is very uncertain and 
more research is needed.  




VERY LOW b,h,i 
The evidence is very uncertain whether chloroquine/hy-
droxychloroquine could affect the rate of ICU admission.  
Cardiac Adverse Events  501 
(5 RCTs)   
VERY LOW b,j,k 
Hydroxychloroquine may significantly increase the rate of ad-
verse events especially QT prolongation and cardiovascular 
death but the evidence is very uncertain.  




VERY LOW a,b,d,e,g 
Current available evidence is very uncertain whether and in 
what direction chloroquine/hydroxychloroquine could affect 










VERY LOW  
The evidence is very uncertain and variable regarding the effect 
of HCQ on the rate of gastrointestinal adverse events (nau-
sea/vomiting/diarrhea) in patients with COVID19.  
 
Explanations 
a. Three studies reported this outcome. None was blinded and one was not randomized.  
b. There is significant heterogeneity in trial results. This might be due to differences in outcome measurements and also study populations.  
c. Total number of patients in the control group=110. confidence intervals  
d. There is special concern for publication bias due to the recent emergence of the disease and the timing of this review. Trials that are not published yet may show different 
results.  
e. None of the studies were placebo-controlled and the standard-of-care which was the control intervention in all of the studies, differed within and across studies. The 
methods of outcome measurement also differed across studies. Another concern is about time from symptom-onset to treatment initiation which is different and not 
described in adequate detail.  
f. Total number of patients in the control group for this outcome =111  
g. Precision is downgraded due to the wide confidence intervals of effect estimates as presented in the results table.  
h. Please refer to risk of bias table.  
i. Total number of events in the control group was 21.  
j. The quality is downgraded due to risk of bias concerns. None of the studies measured the adverse effects systematically. There is a special concern for under detection 
of side effects in the included studies.  
k. Total number of events in control group was 12.  
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In vitro Studies: Recent studies of COVID-19 showed 
promising results with CQ and HCQ in Vero cell models 
reported in 3 studies published in 2020 (13). Also, all stud-
ies, except 1 which used human primary cells, reported the 
efficiency of the drug in cell models. Although the selectiv-
ity index of the studies varied, they generally show that the 
drug is safe. Additionally, the amount of virus used to as-
sess the blocking effect of the drugs on virus replication 
varied between studies, and higher viral inoculates corre-
lated with a higher dose of drug needed to block the virus 
infection. All in vitro studies supported the antiviral effect 
of CQ and HCQ in human coronaviruses, including SARS, 
MERS, and COVID-19. Factors that may limit the applica-
bility of these results include the use of established cell 




Summary of the Evidence 
Figure 2 presents a concept map of the interaction be-
tween HCQ and different mechanisms involved in patho-
genesis of COVID19. 
 
Antiviral Effects of CQ/HCQ 
HCQ has been proposed to have antiviral activity and has 
been used against many viral infections, including HIV (14-
26), influenza (27-32), chikungunya virus (33-39), and 
many other viruses (36, 37, 40-44), albeit with variable lev-
els of clinical effectiveness. Our systematic review reveals 
a consistently positive antiviral effect for HCQ in vitro and 
animal studies; however, these effects varied significantly 
in human studies. Most of human studies used the drug at 
later stages of the illness compared with animal studies, 
which may be the reason for the inconsistency in findings 
across human and animal studies. Moreover, previous stud-
ies have shown that animal studies cannot accurately pre-
dict clinical outcomes in humans (6). This concept has been 
reproduced in our systematic review. Thus, based on these 
limited findings, we cannot conclude whether HCQ is a 
safe and effective antiviral agent for the treatment of 
COVID19.  
 
Immunomodulatory Effects of CQ/HCQ 
COVID-19 is asymptomatic to mildly symptomatic in 
most patients. However, in a smaller number of patients 
with more severe disease, severe inflammatory response, 
cytokine storm, and microphage activation syndrome, it 
may lead to ARDS and multiorgan failure, which may po-
tentially lead to death (45, 46). Cytokine release syndrome 
(CRS) is associated with higher adverse outcomes among 
patients with COVID19 (47-49) and may indirectly de-
crease viral clearance via decreasing T-cell number and 
function (50, 51). Immune modulating drugs such as ster-
oids have been shown to improve outcomes (52, 53).  Hy-
droxychloroquine is one of these potential agents that mod-
ulates immune reaction by decreasing pro-inflammatory 
cytokine release and decreasing the risk of macrophage ac-
tivation syndrome in patients with systemic lupus erythem-
atous without significant immunosuppression (54-60). In 
our systematic review, 2 included clinical studies evaluated 
immunologic markers in COVID-19 patients under treat-
ment with HCQ and found significant reduction in inflam-
matory cytokines in these patients, although the overall 
quality of these studies was very low (61, 62). Three other 
studies compared cytokines (IL-6 and TNF-alpha) between 
HCQ and SOC patients and did not find any significant dif-
ference, but our certainty in these results is also very low 
(63-67).  
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Anticoagulant Effects of CQ/HCQ 
In light of the evidence suggesting hypercoagulable state 
and its possible role in the pathogenesis of severe COVID-
19, this particular pathway may be an important target for 
treatment (68, 69). Anticoagulants have been shown to de-
crease mortality in COVID-19 patients (70). In 1 study, pa-
tients with COVID19-associated pneumonia had a mark-
edly higher level of D-dimer and higher platelet count than 
patients with non-COVID-19-associated pneumonia (71). 
A multicenter study that included 150 patients with 
COVID-associated ARDS found that >95% of the patients 
had an elevated D-dimer level and 50 of 57 of the tested 
patients were positive for lupus anticoagulant antibodies 
(72). Nevertheless, these results are inconsistent with an-
other study which found no association between antiphos-
pholipid antibodies and COVID-19 prothrombotic state 
(73). In another cohort of hospitalized patients with 
COVID-19, the hypercoagulable state in these patients is 
more consistent with a severe inflammatory state than DIC 
(74). HCQ has been shown to decrease thrombotic events 
in patients with antiphospholipid syndrome by interfering 
with assembly of endosomal NADPH oxidase-2, which is 
involved in thrombotic events and affects inflammatory 
state in antiphospholipid syndrome (58, 75).   
 
Drug and Disease-related Adverse Outcomes 
Cardiovascular events, including acute cardiac injury, 
shock, and arrhythmias, were present in 7.2%, 8.7%, and 
16.7% of patients with COVID-19, according to a cohort 
study of hospitalized patients (76). These patients are at an 
increased risk of in-hospital events, including ICU admis-
sion and death (77-79). In a recent study, a combination of 
azithromycin and HCQ was associated with an increase in 
the QTc interval to more than 500 milli seconds in 11% of 
the 84 patients with COVID-19. This effect was signifi-
cantly more common among patients with renal failure 
(80). In a retrospective cohort study on multinational data-
bases collectively including millions of patients, it was 
found that new users of HCQ alone were not at a signifi-
cantly increased risk of adverse effects; nonetheless, its 
combination with azithromycin was associated with an in-
creased risk of death associated with cardiovascular events 
among patients with rheumatoid arthritis (81). These find-
ings present indirect evidence on cardiovascular outcomes 
among chloroquine users. Moreover, the doses and disease-
drug interaction and effect on the heart may differ consid-
erably in COVID-19. Therefore, clinicians should be espe-
cially cautious about the cardiac adverse effects of chloro-
quine, especially its combination with azithromycin or 
Oseltamiovir, and their possible synergistic activity with 
COVID-19 effects on the heart (82).  
Toxicity with quinine agents, including chloroquine and 
HCQ, has also been reported to cause pulmonary side ef-
fects, including an ARDS-like syndrome (83-85), bronchi-
olitis obliterans organizing pneumonia (BOOP) (86), and 
pulmonary edema (87-89). A retrospective study of Wuhan 
patients with COVID-19 reported nervous system involve-
ment among 78 of 214 (36.4%) patients as a part of the clin-
ical presentation in COVID-19. It involves both the periph-
eral and the central nervous system, with symptoms rang-
ing from dizziness and headache to impairments in taste 
and smell and even to stroke, seizures, and encephalitis. 
The proposed pathophysiologic mechanism is a direct brain 
invasion as in SARS and MERS (90). Seizure has also been 
reported with chloroquine use, although this was not con-
firmed in trials as an adverse effect, clinicians should be  
cautious when prescribing this drug in patients with epi-
lepsy (91). 
 
Relevance to Researchers and Care Providers 
The available studies have significant methodological 
limitations, many of which are due to the difficulties asso-
ciated with the special circumstances during a pandemic. 
Whether chloroquine can be clinically effective remains a 
question. One potential reason for the inconsistency be-
tween preclinical and clinical studies can be the interval be-
tween infection and treatment initiation, which may affect 
the potential antiviral effects of chloroquine. We recom-
mend researchers to design trials of chloroquine at earlier 
phases of the infection and among outpatients. We also rec-
ommend systematic and globally homogenous monitoring 
and reporting of the side effects and clinical outcomes. 
 
Relevance to Care providers 
Based on current evidence, we recommend clinicians 
against the routine use of chloroquine/HCQ in patients with 
COVID-19, as the drug has not shown clinical efficacy and 
may be associated with life-threatening side effects, espe-
cially when prescribed with other routinely prescribed med-
ications, such as azithromycin and Oseltamiovir. Thus, spe-
cial care must be taken for patients at risk for QT prolonga-
tion. 
 
Limitations of the Evidence and the Review 
The quality of the included studies was low to very low. 
No placebo-controlled studies were available and only one 
of the studies was blinded. There was significant variation 
in outcomes and methodology across the studies, thus, a 
meta-analysis could not be conducted. All of the studies in-
cluded hospitalized patients only and the results cannot be 
generalized to all patients with COVID-19.  
 
Novelty 
We present a holistic viewpoint by synthesizing the in 
vitro, animal, and human (observational and interventional) 
evidence on the benefits and risks associated with the use 
of chloroquine/HCQ in patients with COVID-19 with a rig-
orous methodology. A few systematic reviews have already 
been published that focused on the same review question. 
However, our study is unique in presenting a holistic ap-
proach combining the results from preclinical studies with 
nonrandomized and randomized human studies and pre-
senting a basic science based clinically oriented viewpoint.  
 
Conclusion 
There is insufficient evidence to draw conclusions on the 
efficacy and safety of chloroquine and Hydroxychloro-
quine based on current evidence. Available studies have 
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Appendix Table 1. Characteristics of Non-Randomized Controlled Human Studies 
Follow-up Outcome Comparison Interventions/Expo-
sure 
Participants Setting Design Study first 
author, Coun-
try 
7 days − transfer to the 
ICU within 7 
days of inclu-
sion 
− transfer to the 
ICU within 7 
days of inclu-
sion and/or 






600 mg/day within 





























600mg with and 
without azithromy-



















gation, (defined as 
QTc interval ≥500 
ms) 
Azithromycin (39), Lop-
inavir/ritonavir (52) or  
azithromycin+Lop-
inavir/ritonavir (9) 
HCQ 400mg or 
600mg (50) 
















longed QT interval) 
AZI alone (211) OR Nei-
ther of the mentioned 
drugs (221) 
Oral HCQ alone 
(271) or HCQ+ AZI 
(735). The dosing 
differed across pa-
tients. The majority 
took HCQ 400 mg 
once to twice daily. 











18 days - all-cause 28-day 
mortality 
- 28-day discharge 
home 
HCQ : 600mg first day, 
400mg daily for the next 
9 days + AZI :500mg on 
the first day followed by 
250mg daily for the next 
4 days (227)  OR neither 
of HCQ or AZI (3792) 
HCQ alone : 600mg 
on the first day, 
400mg daily for the 
next 9 days (623) 
adult inpatients 
with at least one 
PCR-documented 
SARS-CoV-2 







30 days -7-,14-, and 30-day 
mortality 
-need for mechanical 
ventilation 
-incidence of new 
ventricular events (ie: 
fibrillation, tachycar-
dia) or sudden cardiac 
death 
Non-HCQ (910) HCQ (910) 
Varied dosing 
hospitalized adult 
patients (> 18 
years) diagnosed 









10 days -time to unfavorable 
outcome; e.g. death, 
need for ICU admis-
sion 
-time to death 
-time to hospital dis-
charge to home or an 
aftercare unit 
-fever and cough at 
day 5 
-adverse events in the 
HCQ group 
Standard of care only 
(46) 
HCQ 200mg TID 
for 10 days (38) 
All the patients 
hospitalized with 
a diagnosis of 
CoViD-19 via 
RT-PCR from a 
nasopharyngeal 
















































   
   


















































Appendix Table 1. Ctd 
Follow-up Outcome Comparison Interventions/Expo-
sure 
Participants Setting Design Study first 
author, Coun-
try 
14 days -Time to SARS-CoV-
2 negativity test 
-turning negative on 
day 14 
-Time course of in-
flammatory variables 
between admission 
and day seven or 
hospital  discharge 
No HCQ (11) HCQ 400 mg 
twice for day 1, fol-
lowed by 400 mgs 


















-the first occurrence 
of a non-sustained [at 
least 6 sec] or Sus-
tained ventricular 
tachycardia or ventric-





use and the total and 
intensive care unit 
lengths of stay 
Neither drug (SOC) 
81144 
CQ: 765 mg 
[SD=308] for a 
mean of 6.6 
[SD=2.4] days 
(1868) 
HCQ 596 [SD=126] 
mgs for a mean of 
4.2 [SD=1.9] days 
(3016) 
All hospitalized 
















a composite of intuba-
tion 
or death in a time-to-
event analysis 
SOC (565) HCQ: 600mg twice 
on day 1, followed 




adults with a posi-
tive RT-PCR test 
for SARSCoV- 




obtained at any 






At least 9 
days 
-death 
-transfer to ICU 




AZI alone (137) 
Neither drug(162) 
200 mg of oral 
HCQ, three times 
daily for ten days) 
 
HCQ alone (101) 
 
all individuals 
















-the result of the hos-
pitalization (discharge 
or death) 
-the result of hospital-
ization among patients 
requiring ventilation 








8 days -death 
-side effects 
SOC (342) HCQ (441) Positive SARS-
CoV-2 diagnosis 














































   
   


































Appendix Table 2. Characteristics of Randomized Clinical Studies 
Follow-
up 
Outcome Comparison  
(number of patients) 
Interventions/Expo-
sure (number of pa-
tients) 
Participants Setting Design Study first 
author, 
Country 












quine oral 400mg 
daily between day 




Aged >18 years 
(Critical patients ex-
cluded) 




14 days Viral clearance of sputum 
or lower respiratory tract 
secretions 
serious adverse drug event 
within 2 weeks 
the subject's condition 









ment plus oral Hy-
droxychloroquine 
for 5 days (13/15) 
Hospitalized Patients 
with Covid-19 




14 days SARS-CoV-2 RNA was as-
sessed by real-time reverse 
transcription-PCR 
 
Only standard of care 
(75/150) 
Hydroxychloro-
quine oral 1200 mg 
daily for three days 
followed by 800 
mg daily for re-
maining days 
which is either two 
or three weeks de-
pending on the se-
verity  (75/150) 







14 days -mortality by D28; 
-mortality on day 13, par-
ticipant's clinical status, la-
boratorial 
exams, and ECG on days 
13 and 28, daily clinical 
status during hospitaliza-
tion, duration of 
mechanical ventilation (if 
applicable) and supplemen-
tary oxygen (if applicable), 
and the time 
(in days) from treatment in-
itiation to death 
-Adverse events and seri-
ous adverse events 
450mg daily (only 
twice on the first 
day0 or a total of 2.7g 





oral/via an NG-tube 
600mg twice daily 
for 10 days or a to-
tal of 12 gr 




diagnosed with severe 
respiratory syndrome 
resulting from CoVid-








15 days -clinical status at 15 days 
-clinical status at 7 days 
-an indication for intuba-
tion within 15 days 
-the receipt of supplemental 
oxygen administered by a 
high-flow nasal cannula or 
noninvasive ventilation be-
tween randomization and 
15 days 
-the receipt of supplemental 
oxygen administered by a 
high-flow nasal cannula or 
noninvasive ventilation be-





- acute kidney injury 
-and the number of days 
alive and free from respira-
tory support up to 15 days 
SOC (229) HCQ 400mg BD 
for 7 days (221) 
consecutive patients 
who were 18 years of 
age or older and who 
had been hospitalized 
with suspected or con-
firmed Covid-19 with 


















































   
   

























Appendix Table 2. Ctd 
Follow-
up 
Outcome Comparison  
(number of patients) 
Interventions/Exposure 
(number of patients) 
Participants Setting Design Study first 
author, 
Country 
14 days - viral negative transform-
ing time and the negative 
conversion rate of 
SARS CoV 2 RT PCR at 
day 10, 14 of study period 
- the rate of hospital dis-
charge at D ay 14, clinical 
recovery at day 10, CT 
scan improvement at D ay 
10 and 14, and the fre-
quency of adverse events 
Lopinavir/Ritonavir 
400/100 mg BD for 
10 days (12) 
CQ 500mg BD for 10 
days (10) 
Adult patients with 
COVID 19 
according to the diag-
nosis of WHO in-
terim guidance (mild, 
moderate or severe 
CoViD-19) 
inpatient Clinical study Huang, M 
 
Appendix Table 3. Characteristics and Results of Animal Studies 
ID 1 
First Author, study year Dale L Barnard, 2006 
Interventions Amodiaquine; Chloroquine 
Animal model Specific pathogen-free BALB/c female mice (11–18 g) 
Virus model SARS-CoV-1 
Study design 4h before the virus exposure. 
Dosage-forms Chloroquine was used at 50, 10, and 1 mg/kg intraperitoneally and intranasally; and Amodiaquine was used 
at 150, 75, and 10 mg/kg intranasally, and 75, 37.5, 18.8, and 9.4 mg/kg intraperitoneally; twice a day for 3 
days. 
Comparison PBS was used as placebo. 
Number of subjects 15 mice per each concentration of the drugs used in the study 
Tissue Lung 
Length of follow-up 3 days of the start of the treatment where virus was administered at 4 hours post treatment. 
Outcomes Virus titers (Duplicated Log10 CCID50/g) in homogenized lung tissue. 
Results Chloroquine showed no effect on virus titers in vivo when used intraperitoneally. However, it had a statisti-
cally non-significant effect in reducing the virus titers in lung tissues. 
Amodiaquine had no effect at the highest concentration used in the study (150mg/kg) where it did not re-
duce the virus titers at lung tissues. 
Notes The efficiency of the drugs was also tested in vitro in African green monkey cells using different strains of 
the SARS-Cov including Urbani, Toronto 2, Frankfurt 1, CHUK-W1 strains and showed no effect for Chlo-
roquine and two other salts of it but were blocked by Amodiaquine in vitro. Also, both drugs were claimed 





First Author, study year Els Keyaerts, 2009 
Interventions Chloroquine diphosphate 
Animal model Newborn C57BL/6 mice; (El-evage Janvier, Le Genest Saint Isle, France) 
Virus model Coronavirus OC43 (HCoV-OC43) 
Study design In the study two parts were included.  200μl of different dilutions of Chloroquine (corresponding to 1, 5 or 
15 mg/kg of body weight) daily starting from 1 days before/after labor was administered subcutaneously. 
Subsequently, 5-day suckling mice were infected intracerebrally with virus containing 1x103 copy numbers 
of the virus genome and were followed for the outcome as death. The follow up study involved administer-
ing chloroquine at the high dose of 15 mg/kg prepartum and switch the litters for breast feeding. The same 
way the pups were infected, and the survival was followed for 60 days post-infection. A negative control 
group included no drug intervention. 
Dosage-forms Test Prepartum; Group 15mg/kg (9mothers[m]-70pups[p]), Group 5mg/kg (5m-42p), Group 1mg/kg (4m-
21p). Test Postpartum; Group 15mg/kg (11m-76p), Group 5mg/kg (6m-42p), Group 1mg/kg (4m-31p). 
Group placebo (19m-132p). 
Comparison No treatment 
Number of subjects 9 mothers (m)-70 pups (p), 5m-42p, 4m-21p for different dose experiments. Test Postpartum groups 11m-
76p, 6m-42p, 4m-31p for different drug concentrations. Group placebo 19m-132p. 
Tissue Not done 
Length of follow-up Up to 60 days varies between groups 
Outcomes Survival of the pups challenged with live virus 1000 TCID50 intracerebrally 5 days postpartum. 
Results A log rank test indicated that the survival curve for litters that were treated prepartum with 15mg/kg chloro-
quine was significantly different from the survival curves for the pups that were treated prepartum with 
5mg/kg (P= 0.0237), 1mg/kg (P= 0.0001). 100% survived treated 15 mg/kg prepartum (97.4% treated post-
partum). The survival was dose dependent. 
The results of the follow-up study showed that switching the litters between groups of mothers to detect the 
effect of the transplacental or milk delivered chloroquine. The drug was effective when transferred by milk 
and not transplacentally. 
Notes The efficiency of the drug was also tested in vitro using HRT-18 cells and concentration higher than 0.16 
μM results in a decline in the number of HCoV-OC43 copies determined by qRT-PCR. Additionally, the 
15mg/kg drug group survived 100% when used prepartum meaning no adverse effect was associated with 









































   
   








































































Appendix Table 3. Ctd 
ID 3 
First Author, study year Junwei Niu, 2020 
Interventions Chloroquine 
Animal model BALB/c mice (12-days old) 
Virus model rOC43-ns2DelRluc replicative virus based on HCoV-OC43 virus. 
Study design Mice were inoculated with chloroquine and the virus then was administered intracerebrally at 100 TCID50 using 
rOC43-ns2DelRluc, and bioluminescence intensity was measured daily to quantify the virus replication. The tissues 
including brain and spinal cord were studied for the Photon flux and the presence of viral proteins by western blotting. 
The control mice did not get chloroquine before being infected with the virus. 
Dosage-forms Chloroquine was administered to mice 2 h before viral inoculation (day 0; 30 mg/kg) and then administered daily ac-
cording to a previous study of HCoV-OC43-WT (Keyaerts et al., 2009). 
Comparison Drug to PBS as placebo 
Number of subjects 3 mice in virus group and 3 mice in virus + drug group 
Tissue Whole brain and spinal cord 
Length of follow-up 4 days post infection 
Outcomes Survival and the bioluminescence expressed by virus replication as well as the western blot analysis of the luciferase 
activity of the expressed protein in brain and spinal cord. 
Results No signals were detected in mice treated with Chloroquine, and all of them survived, whereas all mice receiving PBS 
displayed increased bioluminescence and died, demonstrating a significant difference relative to the individual controls. 
Also, western blot analysis supported the data of the mice being successfully infected when virus was inoculated. 
Notes The main aim of the study was to optimize and validate the detection of the virus infection in mice and drug treatment 
was used as a control for the whole experiment. The initial dose of 30 mg/kg chloroquine has been reported to be toxic 
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